Last week we described a fragment
library built with the aid of machine learning and designed to contain
privileged fragments that should produce high hit rates. Unfortunately, only
about a tenth of the library members are commercially available, so it will be
some time before we know whether the design was successful. We continue the
theme of fragment libraries with a just published Nat. Commun. paper by György
Keserű (Hungarian Research Centre for Natural Sciences) and a large group of
multinational collaborators (see also here for a nice summary by György).
The researchers started by analyzing
more than 3300 crystal structures of protein-fragment complexes in the protein data bank. Fragments were defined as having 10-16 non-hydrogen atoms, and the
computational approach FTMap was used to ensure that fragments were
binding at hotspots as opposed to spurious, less ligandable sites. This exercise
yielded 3584 fragments, but many of them were identical or very similar to one
another. The researchers used a series of computational tools to cluster
similar fragments (or pharmacophores) and choose a set that would maximize diversity.
This ultimately led them to assemble a library of just 96 fragments, purchased
from five vendors.
This SpotXplorer0 library mostly
follows the rule of three, with 7 to 17 non-hydrogen atoms, MW 100-250 (or 280
for bromine-containing molecules), ≤ 3 hydrogen bond donors, ≤ 8 hydrogen bond
acceptors, and ≤ 3 rotatable bonds. In addition, all members have 1-3 rings, no
more than a single halogen or sulfur atom, and no PAINS. Despite the small
size, this library covers most of the pharmacophores identified in the larger
set, and considerably more than the F2X-Entry fragment library we highlighted last
year or the top five commercial library vendors we noted here.
The researchers then screened
this library against eight targets. Three GPCRs (the serotonin receptors 5-HT1A,
5-HT6, and 5-HT7) were assessed in a cell-based radioligand
displacement assay with fragments at just 10 µM. Despite the low concentration,
4-11 hits were found. Biochemical screens conducted at 800 µM against the
proteases thrombin and Factor Xa yielded 7 and 8 hits respectively. Further
analysis revealed that the SpotXplorer0 ligands sampled a majority of the
pharmacophores found in published fragment hits against theses five targets.
Next the researchers screened
their library against the histone methyltransferase SETD2, an oncology target with
few known attractive ligands. An enzymatic assay yielded two hits, with IC50
values between 300 and 500 µM.
Finally, the SpotXplorer0 library
was part of the XChem crystallographic screens against the SARS-CoV-2 main
protease (Mpro) and Nsp3 macrodomain, which we discussed here and
here. For Mpro, just a single hit was found. This is only half the overall
hit rate for noncovalent fragments in the crystallographic screen against this
target, but the hit is functionally active and has a high ligand efficiency.
The screen against NSP3 yielded five
hits binding at two different sites, for a hit rate of 5.2%. The overall hit
rate against this target was 8%, but that encompasses screens against two
crystal forms of the protein. The crystal form used for SpotXplorer0 had a hit
rate of 21%.
In summary, SpotXplorer0 is new fragment
library that gives high coverage of experimental pharmacophore space. Laudably,
structures of all 96 fragments are provided in the Supplementary Information. But
the jury remains out on how hit-rich the library will be. Interestingly, the F2X-Entry
library we highlighted last year gave considerably higher hit rates of 21% and
30%, albeit against two different targets. SpotXplorer0 is being screened
crystallographically against multiple targets at XChem, and it will be interesting
to see how it performs in the long run.
No comments:
Post a Comment